Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours

Next Previous
Trial Profile

A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX 101 (Primary) ; Dexamethasone; Famotidine; Paracetamol; Promethazine; Ranitidine
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Therapim

    • Most Recent Events

    • 01 Feb 2023 Results(n=25) assessing safety of ATX-101 in patients with advanced solid tumours published in the Oncogene.
    • 09 Nov 2022 Status changed from recruiting to completed, according to a Nordic Nanovector media release.
    • 08 Jun 2021 Results (data cut off Jan 2021, n=22) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top